Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-5922
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy ; volume:57 ; number:11 ; day:17 ; month:9 ; year:2022 ; pages:827 ; date:11.2022
Journal of gastroenterology ; 57, Heft 11 (17.9.2022), 827, 11.2022
- Urheber
-
Kawakubo, Kazumichi
Fernández-del Castillo, Carlos
Liss, Andrew Scott
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00535-022-01922-3
- URN
-
urn:nbn:de:101:1-2023011021074704872019
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kawakubo, Kazumichi
- Fernández-del Castillo, Carlos
- Liss, Andrew Scott
- SpringerLink (Online service)
Ähnliche Objekte (12)
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Clinical immunotherapy in pancreatic cancer
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Epigenetic control of pancreatic cancer metastasis
Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Clinical immunotherapy in pancreatic cancer
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Epigenetic control of pancreatic cancer metastasis
Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Clinical immunotherapy in pancreatic cancer
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Epigenetic control of pancreatic cancer metastasis